文献速递肝病消化道肿瘤与早癌

替诺福韦与恩替卡韦预防慢性乙型肝炎患者肝细胞癌的比较:国际 consortium 研究

Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该回顾性 cohort 研究纳入 6 个国家或地区 19 个中心的 5,537 例初治慢性乙型肝炎患者,比较恩替卡韦(n=4,837)与富马酸替诺福韦二吡呋酯(n=700)单药治疗对肝细胞癌(HCC)发生风险的影响。未调整分析中 TDF 与较低 HCC 风险相关(SHR 0.45,95%CI 0.26-0.79,P=0.005),但多变量调整后关联消失(SHR 0.81,95%CI 0.42-1.56,P=0.52);倾向评分匹配(n=1,040)后两组 HCC 发生率无差异(P=0.51),多变量调整后方案与 HCC 风险仍无关联(adjusted SHR 0.89,95%CI 0.41-1.92,P=0.77)。结论认为 TDF 与 ETV 在预防 CHB 患者 HCC 方面无显著差异。

要点

  • 未调整分析中 TDF 与较低 HCC 风险相关,但多变量调整后关联消失。
  • 倾向评分匹配后 TDF 与 ETV 组 HCC 发生率无显著差异。
  • TDF 与 ETV 在预防 CHB 患者 HCC 方面无显著差异。

核心结论

  • 在慢性乙型肝炎患者中,替诺福韦(TDF)与恩替卡韦(ETV)在预防肝细胞癌(HCC)方面无显著差异。

研究设计与样本

  • 回顾性 cohort 研究,纳入 6 个国家或地区 19 个中心的 5,537 例既往未治疗的 CHB 患者,接受 ETV(n=4,837)或 TDF(n=700)单药治疗。
  • 排除抗病毒治疗前或治疗 1 年内发生 HCC 者,采用竞争风险生存回归和倾向评分匹配(1:1)分析。

主要发现

  • 未调整分析中 TDF 与较低 HCC 风险相关(SHR 0.45,95%CI 0.26-0.79,P=0.005)。
  • 多变量调整年龄、性别、国家、白蛋白、血小板、甲胎蛋白、肝硬化和糖尿病后,TDF 与 HCC 关联不再存在(SHR 0.81,95%CI 0.42-1.56,P=0.52)。
  • 倾向评分匹配(n=1,040)后两组 HCC 发生率无差异(P=0.51),多变量调整后方案与 HCC 风险无关联(adjusted SHR 0.89,95%CI 0.41-1.92,P=0.77)。

临床怎么用

  • 在临床决策中,TDF 与 ETV 均可作为预防 CHB 患者 HCC 的抗病毒选择,两者效果无显著差异。

局限性

  • 本研究为回顾性 cohort 设计,可能存在未测量的混杂因素。
  • TDF 组样本量(n=700)远小于 ETV 组(n=4,837),且匹配前 TDF 组更年轻、疾病程度更轻。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: It is unclear whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) differ in their effectiveness for preventing hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). METHODS: This retrospective cohort study analyzed an international consortium that encompassed 19 centers from 6 countries or regions composed of previously untreated CHB patients then treated with either ETV or TDF monotherapy. Those who developed HCC before antiviral treatment or within 1 year of therapy were excluded. The association between antiviral regimen and HCC risk was evaluated using competing-risk survival regression. We also applied propensity score matching (PSM) to 1:1 balance the 2 treatment cohorts. A total of 5,537 patients were eligible (n = 4,837 received ETV and n = 700 received TDF) and observed for HCC occurrence until December 23, 2018. Before PSM, the TDF cohort was significantly younger and had generally less advanced diseases. RESULTS: In the unadjusted analysis, TDF was associated with a lower risk of HCC (subdistribution hazard ratio [SHR], 0.45; 95% confidence interval [CI], 0.26-0.79; P = 0.005). The multivariable analysis, however, found that the association between TDF and HCC no longer existed (SHR, 0.81; 95% CI, 0.42-1.56; P = 0.52) after adjustment for age, sex, country, albumin, platelet, α-fetoprotein, cirrhosis, and diabetes mellitus. Furthermore, the PSM analysis (n = 1,040) found no between-cohort differences in HCC incidences (P = 0.51) and no association between regimens (TDF or ETV) and HCC risk in the multivariable-adjusted analysis (adjusted SHR, 0.89; 95% CI, 0.41-1.92; P = 0.77). DISCUSSION: TDF and ETV did not significantly differ in the prevention of HCC in patients with CHB.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Hsu YC, Wong GL, Chen CH, et al. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. Am J Gastroenterol. 2020. PMID: 31634265. doi:10.14309/ajg.0000000000000428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。